atuveciclib

a CDK9 inhibitor with antineoplastic activity; structure in first source

Also Known As:

4-(4-fluoro-2-methoxyphenyl)-N-(3-((S-methylsulfonimidoyl)methyl)phenyl)-1,3,5-triazin-2-amine; BAY 1143572

Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - atuveciclib: 8
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - atuveciclib: 8
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Triazines: 306
    - atuveciclib: 8

Experts

1.	Scholz, Arne: 3 articles (12/2018 - 01/2017)
2.	Iida, Shinsuke: 2 articles (12/2018 - 01/2017)
3.	Inagaki, Hiroshi: 2 articles (12/2018 - 01/2017)
4.	Ishida, Takashi: 2 articles (12/2018 - 01/2017)
5.	Ito, Asahi: 2 articles (12/2018 - 01/2017)
6.	Kinoshita, Shiori: 2 articles (12/2018 - 01/2017)
7.	Komatsu, Hirokazu: 2 articles (12/2018 - 01/2017)
8.	Kuroda, Taruho: 2 articles (12/2018 - 01/2017)
9.	Kusumoto, Shigeru: 2 articles (12/2018 - 01/2017)
10.	Masaki, Ayako: 2 articles (12/2018 - 01/2017)

Related Diseases

1.	Neoplasms (Cancer) 11/08/2017 - "Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer." 12/01/2018 - "Orally administering BAY 1143572 once per day to aggressive NK-cell leukemia-bearing mice resulted in lower tumor cell infiltration into the bone marrow, liver, and spleen, with less export to the periphery relative to control mice. " 12/18/2018 - "Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer." 12/01/2018 - "Here, we have assessed the utility of BAY 1143572 for treating natural killer (NK) cell leukemias/lymphomas that have a poor prognosis, namely extranodal NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia, in a preclinical mouse model in vivo as well as in tissue culture models in vitro Seven NK-cell leukemia/lymphoma lines and primary aggressive NK-cell leukemia cells from two individual patients were treated with BAY 1143572 in vitro Primary tumor cells from an aggressive NK-cell leukemia patient were used to establish a xenogeneic murine model for testing BAY 1143572 therapy. " 12/01/2018 - "In aggressive NK-cell leukemia primary tumor cells, exposure to BAY 1143572 in vitro resulted in decreased Mcl-1 protein levels resulting from inhibition of RNA polymerase II C-terminal domain phosphorylation at the serine 2 site. "
2.	Necrosis 12/01/2021 - "This study was designed to analyse the effects of the novel, orally bioavailable CDK9-inhibitor Atuveciclib (BAY 1143572) in combination with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) on pancreatic ductal adenocarcinoma (PDAC) cancer cells. "
3.	Adenocarcinoma 12/01/2021 - "This study was designed to analyse the effects of the novel, orally bioavailable CDK9-inhibitor Atuveciclib (BAY 1143572) in combination with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) on pancreatic ductal adenocarcinoma (PDAC) cancer cells. "
4.	Triple Negative Breast Neoplasms 12/18/2018 - "Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer."
5.	Intervertebral Disc Degeneration 01/01/2020 - "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-κB Signaling Pathway."

Related Drugs and Biologics

1.	atuveciclib
2.	Ligands
3.	Cyclin-Dependent Kinase 9
4.	Serine (L-Serine)
5.	RNA Polymerase II (RNA Polymerase B)
6.	Proteins (Proteins, Gene)
7.	Antineoplastic Agents (Antineoplastics)
8.	nutlin 3
9.	pitavastatin (itavastatin)

Related Therapies and Procedures

1.	Therapeutics